Literature DB >> 17937416

Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent.

Kishore Udipi1, Mingfei Chen, Peiwen Cheng, Kevin Jiang, Diane Judd, Alejandra Caceres, Robert J Melder, Josiah N Wilcox.   

Abstract

Drug-eluting stents have proven superior to bare metal stents with lower restenosis rates. Local delivery of drugs from these stents is achieved in most cases with the help of biostable polymer coatings. However, since the polymer coating remains in the body well after all the drug is released, patients can potentially develop hypersensitivity to these polymers--leading to complications such as late-stent thrombosis. It is therefore important that the polymers are designed to be biocompatible and well tolerated by the body. The polymer coatings are also expected to be robust and provide good control over elution of the desired drug. This paper describes the development of a unique, proprietary polymer blend system, specially designed to meet these requirements. Mutually compatible, free-radical-initiated elastomeric polymers were designed to provide a robust coating and offer a steady, sustained release of the highly hydrophobic drug zotarolimus over an extended period. The polymer blend system is also well tolerated by the hydrophilic environment in vivo, as demonstrated through porcine studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17937416     DOI: 10.1002/jbm.a.31664

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  11 in total

1.  Bacterial colonization of bone allografts: establishment and effects of antibiotics.

Authors:  Constantinos Ketonis; Stephanie Barr; Christopher S Adams; Noreen J Hickok; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2010-08       Impact factor: 4.176

2.  Topographic features retained after antibiotic modification of Ti alloy surfaces: retention of topography with attachment of antibiotics.

Authors:  Constantinos Ketonis; Javad Parvizi; Christopher S Adams; Irving M Shapiro; Noreen J Hickok
Journal:  Clin Orthop Relat Res       Date:  2009-04-14       Impact factor: 4.176

3.  Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months' follow-up: an optical coherence tomography study.

Authors:  Takehiro Hashikata; Taiki Tojo; Sayaka Namba; Lisa Kitasato; Takuya Hashimoto; Ryo Kameda; Takao Shimohama; Minako Yamaoka-Tojo; Junya Ako
Journal:  Heart Vessels       Date:  2014-11-02       Impact factor: 2.037

4.  Durable Polymer Drug Eluting Stent-Induced Kounis Syndrome and Eosinophilia Requiring Long-term Immunosuppression.

Authors:  Thomas Boucher; Aman M Shah; Hayder Hashim; Elina Jerschow; Anna E Bortnick
Journal:  Can J Cardiol       Date:  2021-12-10       Impact factor: 5.223

5.  Location-dependent coronary artery diffusive and convective mass transport properties of a lipophilic drug surrogate measured using nonlinear microscopy.

Authors:  Joseph T Keyes; Bruce R Simon; Jonathan P Vande Geest
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

6.  Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial.

Authors:  Juan Luis Gutiérrez-Chico; Robert Jan van Geuns; Evelyn Regar; Willem J van der Giessen; Henning Kelbæk; Kari Saunamäki; Javier Escaned; Nieves Gonzalo; Carlo di Mario; Francesco Borgia; Eveline Nüesch; Héctor M García-García; Sigmund Silber; Stephan Windecker; Patrick W Serruys
Journal:  Eur Heart J       Date:  2011-06-09       Impact factor: 29.983

7.  One-year clinical outcomes of patients implanted with a Resolute Onyx™ zotarolimus-eluting stent.

Authors:  Chor Cheung Tam; Kelvin Chan; Simon Lam; Arthur Yung; Yui Ming Lam; Carmen Chan; David Siu; Hung Fat Tse
Journal:  J Int Med Res       Date:  2017-07-31       Impact factor: 1.671

8.  Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial.

Authors:  Doo Sun Sim; Myung Ho Jeong; Young Joon Hong; Ju Han Kim; Youngkeun Ahn; Keun Ho Park; Sun Ho Hwang; Dong Goo Kang; Seung Uk Lee; Joon Woo Kim; Jong Pil Park; Jay Young Rhew; Sang Rok Lee; Jei Keon Chae; Kyeong Ho Yun; Seok Kyu Oh; Won You Kang; Su Hyun Kim; Jang Hyun Cho
Journal:  Chonnam Med J       Date:  2018-01-25

9.  Comparison of the Major Clinical Outcomes for the Use of Endeavor® and Resolute Integrity® Zotarolimus-Eluting Stents During a Three-Year Follow-up.

Authors:  Yong Hoon Kim; Ae-Young Her; Seung-Woon Rha; Byoung Geol Choi; Se Yeon Choi; Jae Kyeong Byun; Yoonjee Park; Dong Oh Kang; Won Young Jang; Woohyeun Kim; Cheol Ung Choi; Chang Gyu Park; Hong Seog Seo
Journal:  Glob Heart       Date:  2020-02-06

10.  Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study.

Authors:  Tomasz Roleder; Elvin Kedhi; Balazs Berta; Pawel Gasior; Wojciech Wanha; Magda Roleder; Joanna Fluder; Grzegorz Smolka; Andrzej Ochala; Wojciech Wojakowski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-06-26       Impact factor: 1.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.